タバタ　ツトム   TABATA Tsutomu   田畑　務    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	Trends in Pregnancy-Associated Cervical Cancer in Japan between 2012 and 2017: A Multicenter Survey.
掲載誌名	正式名：Cancers 略　 称：Cancers (Basel) ISSNコード：20726694/20726694
掲載区分	国内
巻・号・頁	14(13),pp.1-13
著者・共著者	Enomoto Sayako, Yoshihara Kosuke, Kondo Eiji, Iwata Akiko, Tanaka Mamoru, Tabata Tsutomu, Kudo Yoshiki, Kondoh Eiji, Mandai Masaki, Sugiyama Takashi, Okamoto Aikou, Saito Tsuyoshi, Enomoto Takayuki, Ikeda Tomoaki
担当区分	責任著者
発行年月	2022/06
概要	Large-scale data on maternal and neonatal outcomes of pregnancy-associated cervical cancer in Japan are scarce, and treatment strategies have not been established. This multicenter retrospective observational study investigated clinical features and trends in pregnancy-associated cervical cancer treatments at 523 hospitals in Japan. We included cervical cancer cases that were histologically diagnosed (between 1 January 2012, and 31 December 2017), and their clinical information was retrospectively collected. Of 40 patients diagnosed with pregnancy-associated cervical cancer at ≥22 gestational weeks, 34 (85.0%) were carefully followed until delivery without intervention. Of 163 diagnosed at <22 gestational weeks, 111 continued and 52 terminated their pregnancy. Ninety patients with stage IB1 disease had various treatment options, including termination of pregnancy. The 59 stage IB1 patients who continued their pregnancy were categorized by the primary treatment into strict follow-up, conization, trachelectomy, and neoadjuvant chemotherapy groups, with no significant differences in progression-free or overall survival. The birth weight percentile at delivery was smaller in the neoadjuvant chemotherapy group than in the strict follow-up group (p = 0.029). Full-term delivery rate was relatively higher in the trachelectomy group (35%) than in the other groups. Treatment decisions for pregnancy-associated cervical cancer are needed after estimating the stage, considering both maternal and fetal benefits.
DOI	10.3390/cancers14133072
PMID	35804845